Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/04/23
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial StrategyBusiness Wire • 11/22/22
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/02/22
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesBusiness Wire • 11/02/22
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022Business Wire • 10/27/22
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority ReviewBusiness Wire • 10/26/22
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual MeetingsBusiness Wire • 10/23/22
Seres Therapeutics' ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical AssociationBusiness Wire • 10/19/22
Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual MeetingBusiness Wire • 10/12/22
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile InfectionBusiness Wire • 09/07/22
Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth ConferenceBusiness Wire • 08/04/22
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/03/22
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdatesBusiness Wire • 08/03/22
Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022Business Wire • 07/28/22
Seres Therapeutics Announces $100 Million Registered Direct Offering of Common StockBusiness Wire • 06/30/22
Seres Therapeutics: As Biotech Fades The Case For Seres Investment StrengthensSeeking Alpha • 06/09/22
Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome DrugBenzinga • 06/07/22